NDAORALTABLET
Approved
Nov 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
ACCUPRIL (quinapril hydrochloride) by R-Pharm US is clinical pharmacology mechanism of action quinapril is deesterified to the principal metabolite, quinaprilat, which is an inhibitor of ace activity in human subjects and animals. Approved for hypertension, to lower blood pressure, the management of heart failure and 3 more indications. First approved in 1991.
Drug data last refreshed 1w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ACCUPRIL (quinapril hydrochloride) is an oral ACE inhibitor approved in 1991 for hypertension and heart failure management. It works by inhibiting angiotensin-converting enzyme, reducing angiotensin II formation and aldosterone secretion, thereby lowering blood pressure and reducing cardiac workload.
LOE Approaching
Product approaching loss of exclusivity with limited commercial growth; team size and investment likely stable or declining as generic competition increases.
Mechanism of Action
CLINICAL PHARMACOLOGY Mechanism of Action Quinapril is deesterified to the principal metabolite, quinaprilat, which is an inhibitor of ACE activity in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor, angiotensin II. The…
Worked on ACCUPRIL at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.